<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591691</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00168547</org_study_id>
    <secondary_id>1U24DK122927-01</secondary_id>
    <nct_id>NCT04591691</nct_id>
  </id_info>
  <brief_title>C-myc Biomarker Study for Diabetic Foot Ulcers</brief_title>
  <official_title>Predictive and Diagnostic Biomarkers for Diabetic Foot Ulcers - C-myc and Phosphorylated Glucocorticoid Receptor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center observational cohort study of patients with diabetic foot ulcers (DFU)&#xD;
      to develop and validate potential tissue-based biomarkers that predict complete wound&#xD;
      healing. Eligible and consented participants will begin standard of care treatment after&#xD;
      collection of tissue specimens from the wound's edge. An additional tissue specimen is&#xD;
      collected at 4 weeks. Tissues will be tested for c-myc and phosphorylated glucocorticoid&#xD;
      receptor (p-GR) levels using validated protocols at a central laboratory. Participants will&#xD;
      be followed weekly for up to 12 weeks or until complete wound healing (whichever occurs&#xD;
      first). One final assessment 2 weeks after complete wound healing will occur to confirm&#xD;
      healing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with complete wound healing by week 12, defined as complete wound closure where there is skin re-epithelialization without drainage or dressing requirements</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">213</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetic Foot</condition>
  <condition>Diabetic Foot Ulcer</condition>
  <condition>Diabetic Wound</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Using a 3mm punch biopsy device, two adjacent tissue specimens are collected from the wound&#xD;
      edge at Week 0 and Week 4 of the study.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult Type 1 or Type 2 Diabetic patients with a diabetic foot ulcer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, an individual must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 18 years or older.&#xD;
&#xD;
          4. Clinically diagnosed with diabetes or meeting the American Diabetes Association (ADA)&#xD;
             criteria.&#xD;
&#xD;
          5. Foot ulcer of diabetic etiology, with all of the following characteristics:&#xD;
&#xD;
               1. Ulcer size &gt; 0.5 cm2and &lt; 12 cm2 at least 2 cm from any other ulcer, and&#xD;
&#xD;
               2. Ulcer with Wagner grade 1 or 2 In case of multiple ulcers, select the largest&#xD;
                  ulcer that meets inclusion criteria.&#xD;
&#xD;
          6. Patients with neuropathic or neuro-ischemic ulcers with adequate circulation to allow&#xD;
             healing to the affected extremity as demonstrated by at least 2 of the following:&#xD;
&#xD;
               1. Ankle brachial index (ABI) ≥ 0.6 with Doppler Waveforms, or&#xD;
&#xD;
               2. Absolute ankle pressure ≥ 70 mm Hg, or&#xD;
&#xD;
               3. Toe pressure ≥ 40 mmHg, or&#xD;
&#xD;
               4. TcPO2 ≥ 40 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          1. Patient participating in an interventional clinical trial within 1 month of Visit 1&#xD;
&#xD;
          2. Currently receiving radiation to target area or chemotherapy&#xD;
&#xD;
          3. Participants with Charcot's foot or other foot deformities that prevents adequate&#xD;
             targeted ulcer offloading&#xD;
&#xD;
          4. Participant with active severe infection or osteomyelitis at the time of screening&#xD;
&#xD;
          5. History of cancer within last 3 years, other than non-melanoma skin cancer&#xD;
&#xD;
          6. Known or suspected malignancy of current study ulcer&#xD;
&#xD;
          7. Use of adjunctive therapy within previous 30 days&#xD;
&#xD;
          8. Currently receiving medication considered to be systemic glucocorticoids&#xD;
&#xD;
          9. Plan to perform a vascular intervention, such as surgical bypass, angioplasty or&#xD;
             stenting, or &lt; 1 month from a prior ipsilateral vascular intervention&#xD;
&#xD;
         10. Any history of concomitant medical condition that, in the opinion of the&#xD;
             investigator(s), would compromise the participant's ability to safely complete the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjana Tomic-Canic</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katy Clark</last_name>
    <phone>734-615-6767</phone>
    <email>katymc@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brandi Gizinski</last_name>
    <phone>7347637810</phone>
    <email>njra@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Onorio Antonucci</last_name>
      <phone>415-353-4379</phone>
      <email>onorio.antonucci@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Conte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Meyer</last_name>
      <email>smeyer72@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Gurtner, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aliette Espinosa</last_name>
      <phone>305-689-3376</phone>
      <email>a.espinosa2@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Robert S Kirsner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryce Hockman</last_name>
      <phone>317-278-2715</phone>
      <email>bbhockma@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Henry Ludwig</last_name>
      <phone>317-504-5785</phone>
      <email>hbludwig@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chandan K Sen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Burant</last_name>
      <phone>734-615-0552</phone>
      <email>aburant@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Rodica Pop-Busui, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>25261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Cathie Spino, ScD</investigator_full_name>
    <investigator_title>Research Professor of Biostatistics, SABER Director</investigator_title>
  </responsible_party>
  <keyword>biomarker</keyword>
  <keyword>C-myc</keyword>
  <keyword>phosphorylated glucocorticoid receptor</keyword>
  <keyword>DFC</keyword>
  <keyword>Diabetic Foot Consortium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

